ArticleFrontiers in immunology2025
Successful surgical management of unresectable stage IIIB LSCC following neoadjuvant chemotherapy combined with toripalimab: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has emerged as a promising strategy to improve the survival of patients with cancer. This case report presents a patient with unresectable advanced lung squamous cell carcinoma (LSCC) who successfully underwent surgical resection following neoadjuvant treatment with toripalimab and chemotherapy. Chest computed tomographic (CT) scan revealed mass lesions in both upper lungs, with the left upper lesion measuring approximately 5.6 × 4.6 cm. A CT-guided biopsy confirmed LSCC in the left upper lung. Enhanced chest CT at our hospital indicated a left upper lobe tumor measuring approximately 5.6 × 5.0 cm, with possible invasion of the left pulmonary artery and multiple enlarged mediastinal and ipsilateral hilar lymph nodes. A nodule in the apical segment of the right upper lobe was noted. The patient was staged as cT4N2M0, stage IIIB, and received three cycles of toripalimab (240 mg) combined with cisplatin (120 mg) and paclitaxel (300 mg). Mild nausea occurred during treatment. Follow-up enhanced CT demonstrated the left upper lobe lesion reduced to approximately 4.4 × 3.3 cm. The patient subsequently underwent thoracoscopic left upper lobectomy, mediastinal lymphadenectomy, and pulmonary artery reconstruction after treatment. Postoperative symptomatic supportive care included infection control, airway clearance, and nebulization. The patient was discharged on the sixth postoperative day. This case demonstrates that immunochemotherapy may enable surgical intervention in patients with unresectable lung cancer, potentially improving patient outcomes and informing future clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.